 Geneva, Switzerland and Boston, MA August 7, 2020 ObsEva SA NASDAQ: OBSV, a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the Wedbush PacGrow Virtual Healthcare Conference taking place August 11 - 12, 2020.Mr. Loumayes presentation will take place on Wednesday August 12, 2020 at 9:45 a.m. Eastern Time ET. A live presentation link will be available under Events Calendar in the investors section of ObsEvas website at About ObsEvaObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol OBSV and on the SIX Swiss Exchange where it is trading under the ticker symbol OBSN. For more information, please visit For further information, please contact: CEO Office contact Shauna Dillon 41 22 552 1550Investor Contact Mario Corso Vice President, Investor Relations 857 972 9347 Office 1 781 366 5726 Mobile Attachment Press Release in Pdf 